Syngeneic hematopoietic stem cell transplantation enhances the antitumor immunity of intratumoral type i interferon gene transfer for sarcoma

Human Gene Therapy

Volumn 23, Issue 2, 2012, Pages 173-186

  Udagawa, Takeshi ^a,b   Narumi, Kenta ^a   Goto, Naoko ^a   Aida, Kouichirou ^a   Suzuki, Koji ^a   Ochiya, Takahiro ^a   Makimoto, Atsushi ^c   Yoshida, Teruhiko ^a   Chikaraishi, Tatsuya ^b   Aoki, Kazunori ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; PLASMID VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL DEATH; CONTROLLED STUDY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; IN VIVO STUDY; ISOGRAFT; LIVER METASTASIS; LUNG METASTASIS; MOUSE; NONHUMAN; OSTEOSARCOMA; SARCOMA CELL; TUMOR IMMUNITY; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CELL LINE, TUMOR; FEMALE; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY; INTERFERON-BETA; LIPIDS; MICE; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; PLASMIDS; SARCOMA, EXPERIMENTAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MURINAE; MUS;

EID: 84863118887     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2011.046     Document Type: Article

References (48)

1. Ahmed, C.M., Wills, K.N., Sugarman, B.J., et al. (2001). Selective expression of nonsecreted interferon by an adenoviral vector confers antiproliferative and antiviral properties and causes reduction of tumor growth in nude mice. J. Interferon Cytokine Res. 21, 399-408. (Pubitemid 32692461)
2. Antman, K.H. (1997). Adjuvant therapy of sarcomas of soft tissue. Semin. Oncol. 24, 556-560. (Pubitemid 27449592)
3. Asavaroengchai, W., Kotera, Y., and Mule, J.J. (2002). Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc. Natl. Acad. Sci. U.S.A. 99, 931-936. (Pubitemid 34106613)
4. Baccala, R., Gonzalez-Quintial, R., Dummer, W., and Theofilopoulos, A.N. (2005). Tumor immunity via homeostatic T cell proliferation: mechanistic aspects and clinical perspectives. Springer Semin. Immunopathol. 27, 75-85. (Pubitemid 40905064)
5. Bacci, G., Briccoli, A., Longhi, A., et al. (2005). Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy. Acta Oncol. 44, 748-755. (Pubitemid 41547077)
6. Barnes, B.J., Kellum, M.J., Pinder, K.E., et al. (2003). Interferon regulatory factor 5, a novel mediator of cell cycle arrest and cell death. Cancer Res. 63, 6424-6431. (Pubitemid 37255192)
7. Belardelli, F., Ferrantini, M., Proietti, E., and Kirkwood, J.M. (2002). Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 13, 119-134. (Pubitemid 34229387)
8. Benedict, W.F., Tao, Z., Kim, C.S., et al. (2004). Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein. Mol. Ther. 10, 525-532. (Pubitemid 39186113)
9. Borden, E.C., Amato, D.A., Edmonson, J.H., et al. (1990). Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft-tissue sarcomas. Cancer 66, 862-867. (Pubitemid 20307916)
10. Borrello, I., Sotomayor, E.M., Rattis, F.M., et al. (2000). Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines. Blood 95, 3011-3019. (Pubitemid 30321148)
11. Brodowicz, T., Wiltschke, C., Kandioler-Eckersberger, D., et al. (1999). Inhibition of proliferation and induction of apoptosis in soft tissue sarcoma cells by interferon-alpha and retinoids. Br. J. Cancer 80, 1350-1358. (Pubitemid 29308602)
12. Chou, A.J., Merola, P.R., Wexler, L.H., et al. (2005). Treatment of osteosarcoma at first recurrence after contemporary therapy: the Memorial Sloan-Kettering Cancer Center experience. Cancer 104, 2214-2221. (Pubitemid 41579969)
13. De Palma, M., Mazzieri, R., Politi, L.S., et al. (2008). Tumortargeted interferon-a delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell 14, 299-311.
14. Dudley, M.E., Yang, J.C., Sherry, R., et al. (2008). Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26, 5233-5239.
15. Dummer, W., Niethammer, A.G., Baccala, R., et al. (2002). T cell homeostatic proliferation elicits effective antitumor autoimmunity. J. Clin. Invest. 110, 185-192. (Pubitemid 34787355)
16. Einhorn, S., and Grander, D. (1996). Why do so many cancer patients fail to respond to interferon therapy? J. Interferon Cytokine Res. 16, 275-281. (Pubitemid 26132339)
17. Ferrantini, M., Capone, I., and Belardelli, F. (2007). Interferonalpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie 89, 884-893. (Pubitemid 47001642)
18. Ferrantini, M., Capone, I., and Belardelli, F. (2008). Dendritic cells and cytokines in immune rejection of cancer. Cytokine Growth Factor Rev. 19, 93-107. (Pubitemid 351200063)
19. Filatenkov, A., Muller, A.M., Tseng, W.W., et al. (2009). Ineffective vaccination against solid tumors can be enhanced by hematopoietic cell transplantation. J. Immunol. 183, 7196-7203.
20. Fujioka, N., Ariyasu, T., Arai, N., et al. (2006). Role of p53 in the inhibitory effects of interferon-alpha subtypes on proliferation of hepatocellular carcinoma cells. Biomed. Res. 27, 219-226. (Pubitemid 44768650)
21. Gattinoni, L., Finkelstein, S.E., Klebanoff, C.A., et al. (2005). Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8 + T cells. J. Exp. Med. 202, 907-912. (Pubitemid 41396891)
22. Hara, H., Kobayashi, A., Yoshida, K., et al. (2007). Local interferon-alpha gene therapy elicits systemic immunity in a syngeneic pancreatic cancer model in hamster. Cancer Sci. 98, 455-463. (Pubitemid 46195620)
23. Hara, H., Kobayashi, A., Narumi, K., et al. (2009). Intratumoral interferon-alpha gene transfer enhances tumor immunity after allogeneic hematopoietic stem cell transplantation. Cancer Immunol. Immunother. 58, 1007-1021.
24. Hatanaka, K., Suzuki, K., Miura, Y., et al. (2004). Interferon-alpha and antisense K-ras RNA combination gene therapy against pancreatic cancer. J. Gene Med. 6, 1139-1148. (Pubitemid 40228126)
25. Hottiger, M.O., Dam, T.N., Nickoloff, B.J., et al. (1999). Liposome-mediated gene transfer into human basal cell carcinoma. Gene Ther. 6, 1929-1935. (Pubitemid 30076863)
26. Jing, W., Orentas, R.J., and Johnson, B.D. (2007). Induction of immunity to neuroblastoma early after syngeneic hematopoietic stem cell transplantation using a novel mouse tumor vaccine. Biol. Blood Marrow Transplant. 13, 277-292.
27. Kempf-Bielack, B., Bielack, S.S., Jurgens, H., et al. (2005). Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J. Clin. Oncol. 23, 559-568. (Pubitemid 46224233)
28. Kobayashi, A., Hara, H., Ohashi, M., et al. (2007). Allogeneic MHC gene transfer enhances an effective antitumor immunity in the early period of autologous hematopoietic stem cell transplantation. Clin. Cancer Res. 13, 7469-7479.
29. Link, M.P., Goorin, A.M., Miser, A.W., et al. (1986). The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N. Engl. J. Med. 314, 1600-1606. (Pubitemid 16118216)
30. Longhi, A., Errani, C., De Paolis, M., et al. (2006). Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat. Rev. 32, 423-436. (Pubitemid 44309249)
31. Müller, C.R., Smeland, S., Bauer, H.C., et al. (2005). Interferon-a as the only adjuvant treatment in high-grade osteosarcoma: long term results of the Karolinska Hospital series. Acta Oncol. 44, 475-480. (Pubitemid 41191780)
32. Narumi, K., Kondoh, A., Udagawa, T., et al. (2010). Administration route-dependent induction of antitumor immunity by interferon-alpha gene transfer. Cancer Sci. 101, 1686-1694.
33. Ohashi, M., Yoshida, K., Kushida, M., et al. (2005). Adenovirusmediated interferon alpha gene transfer induces regional direct cytotoxicity and possible systemic immunity against pancreatic cancer. Br. J. Cancer 93, 441-449. (Pubitemid 43080018)
34. Pfeffer, L.M., Dinarello, C.A., Herberman, R.B., et al. (1998). Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res. 58, 2489-2499. (Pubitemid 28275413)
35. Rabinovich, G.A., Gabrilovich, D., and Sotomayor, E.M. (2007). Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 25, 267-296. (Pubitemid 46697910)
36. Rodriguez, E.G. (2004). Nonviral DNA vectors for immunization and therapy: design and methods for their obtention. J. Mol. Med. 82, 500-509. (Pubitemid 39149860)
37. Salmon, P., Le Cotonnec, J.Y., Galazka, A., et al. (1996). Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers. J. Interferon Cytokine Res. 16, 759-764. (Pubitemid 26389112)
38. Santini, S.M., Lapenta, C., Santodonato, L., et al. (2009). IFNalpha in the generation of dendritic cells for cancer immunotherapy. Handb. Exp. Pharmacol. 295-317.
39. Sarcoma Meta-analysis Collaboration. (1997). Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet 350, 1647-1654.
40. Shang, D., Yang, P., Liu, Y., et al. (2011). Interferon-alpha induces G1 cell-cycle arrest in renal cell carcinoma cells via activation of Jak-Stat signaling. Cancer Invest. 29, 347-352.
41. Strander, H. (2007). Interferons and osteosarcoma. Cytokine Growth Factor Rev. 18, 373-380. (Pubitemid 47302835)
42. Studeny, M., Marini, F.C., Dembinski, J.L., et al. (2004). Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J. Natl. Cancer Inst. 96, 1593-1603. (Pubitemid 39534883)
43. Thulasi, R., Dias, P., Houghton, P.J., and Houghton, J.A. (1996). Alpha 2a-interferon-induced differentiation of human alveolar rhabdomyosarcoma cells: correlation with down-regulation of the insulin-like growth factor type I receptor. Cell Growth Differ. 7, 531-541. (Pubitemid 26362097)
44. Wang, L.X., Li, R., Yang, G., et al. (2005). Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing. Cancer Res. 65, 10569-10577. (Pubitemid 41743752)
45. Whelan, J., Patterson, D., Perisoglou, M., et al. (2010). The role of interferons in the treatment of osteosarcoma. Pediatr. Blood Cancer 54, 350-354.
46. Wrzesinski, C., and Restifo, N.P. (2005). Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy. Curr. Opin. Immunol. 17, 195-201. (Pubitemid 40343108)
47. Yoshida, J., Mizuno, M., and Wakabayashi, T. (2004). Interferonbeta gene therapy for cancer: basic research to clinical application. Cancer Sci. 95, 858-865. (Pubitemid 40045519)
48. Zhang, J.F., Hu, C., Geng, Y., et al. (1996). Treatment of a human breast cancer xenograft with an adenovirus vector containing an interferon gene results in rapid regression due to viral oncolysis and gene therapy. Proc. Natl. Acad. Sci. U.S.A. 93, 4513-4518. (Pubitemid 26144318)